Respiratory syncytial virus vial.
Manjurul | Istock | Getty Images
Pfizer‘s vaccine against respiratory syncytial virus maintained protection for older adults across two full seasons of the disease in an ongoing late-stage clinical trial, the corporate announced Thursday.
The shot’s efficacy declined barely compared with the degrees of protection after one RSV season, but the brand new data suggests that the jab generally offers durable protection for adults ages 60 and above, who’re more vulnerable to severe illness from RSV. The launch of Pfizer’s vaccine, referred to as Abrysvo, and one other RSV shot from GlaxoSmithKline last yr proved to be a boon for each firms, with the jabs accounting for tons of of thousands and thousands in only half a yr in the marketplace.
A single dose of Pfizer’s vaccine was 77.8% effective against more severe lower respiratory tract illness with three or more symptoms through a second season, down from the 88.9% efficacy following the top of 1 season. Those symptoms include wheezing, shortness of breath, rapid and shallow respiration, and mucus production.
The shot was roughly 55.7% effective against a less severe type of that condition with two or more symptoms after the top of season two, in accordance with the initial data on greater than 37,000 participants within the Northern and Southern Hemispheres. The jab showed 66.7% efficacy against that condition after one RSV season.
Pfizer noted that the vaccine showed consistent efficacy against RSV A and RSV B, that are the two major subtypes of the virus, after the second RSV season. The shot was specifically 80% or more practical against each type in patients with the more severe type of lower respiratory tract illness.
No recent adversarial events were reported by patients after the two seasons.
The outcomes come ahead of a gathering of an advisory panel to the Centers for Disease Control and Prevention on Thursday, which is able to consider whether seniors should take RSV shots annually or every other yr.
Analysts don’t expect the committee to make a final suggestion until June – a call which will have huge implications for Moderna, which is hoping to launch its own RSV jab this yr.
Jefferies analyst Michael Yee said in a note last week that the firm sees a 50% to 70% likelihood that the panel will recommend annual vaccination, which might put Moderna able to attain “a minimum of equivalent market share” to Pfizer and GSK. A biennial suggestion based on data on GSK’s shot across two seasons would “reduce competitive positioning” for Moderna, he noted.
In older adults, GSK’s shot showed a cumulative efficacy of 67.2% against lower respiratory tract illness over two RSV seasons. That is compared with 82.6% after one season of the virus.
GSK’s vaccine booked around £1.2 billion ($1.5 billion) in sales last yr. Meanwhile, Pfizer’s shot, which can be approved for expectant moms who can pass on protection to their children, recorded about $890 million in revenue in 2023.
RSV kills 6,000 to 10,000 older adults and hospitalizes 60,000 to 160,000 of them every yr, in accordance with the CDC.
Don’t miss these stories from CNBC PRO: